Roy D. Baynes, Director at Travere Therapeutics, Inc. (TVTX), sold 16,000 shares at $20.00 ($320K) on 2025-01-23, disclosed to the SEC on 2025-01-23.
Scheduled sale ($320k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-05-04 | $431K | — | Filing → |
| TVTX | SELL | 2026-04-16 | $1.4M | — | Filing → |
| TVTX | SELL | 2026-04-07 | $330K | — | Filing → |